Li Songfeng, Deng Guangda, Liu Jinghua, Ma Yan, Lu Hai
Beijing Ophthalmology and Visual Science Key Laboratory, Beijing Tongren Eye Center, Beijing Tongren Hospital,Capital Medical University, No. 1 Dongjiao Min Xiang, 100730, Beijing, People's Republic of China.
BMC Ophthalmol. 2017 May 22;17(1):76. doi: 10.1186/s12886-017-0469-4.
To examined the curative effect of vitreous injection with ranibizumab,laser coagulation and cryotherapy in treating stage 3 Coats' disease with exudative retinal detachment.
Seventeen patients with stage 3 Coats' disease were enrolled in the study. All eyes were treated with vitreous injection of ranibizumab as initial treatment, and subsequent treatment depended on the absorption of subretinal fluid, Including cryotherapy and laser photocoagulation. Repeat treatment for the two treatment intervals occurred in ≥1 month. The mean follow-up time was 24.12 ± 5.99 months. The main data evaluation and outcome measurements included the patient's vision, intraocular pressure(IOP), optical coherence tomography (OCT), slit lamp examination, indirect ophthalmoscopy, color Doppler imaging (CDI) and color fundus image analysis. The following variables were compared between groups: abnormal vascular changes, subretinal fluid and exudate absorption, retinal reattachment and complications. The final follow-up results were used to determine the effectiveness of treatment.
Of the 17 patients included, 88.24% were male and 11.76% were female. Visual acuity was less than 0.02 in 12 eyes before surgery and 8 eyes after surgery. Visual acuity improved in 7 eyes, accounting for 41.18% of cases, and remained unchanged in 7 eyes, accounting for 41.18% of cases. Three patients were too young to undergo the operation, accounting for 17.65% of cases. The best vision was 0.1. Patients were treated 1 to 5 times for an average of 2.82 ± 0.95 times each. There was no statistically significant difference (t = 1.580, p = 0.135) between the preoperative and postoperative intraocular pressures. However, there was a statistically significant difference between the preoperative and postoperative retinal detachment height (2- related samples Wilcoxon signed rank test with z = 3.517, p = 0.000). The results further showed that all patients had different degrees of subretinal fluid absorption, and some of the new blood vessels subsided. All patients were successfully treated with laser and cryosurgery. No ocular or systemic complications were observed during follow-up.
Intravitreal ranibizumab (IVR), laser coagulation and cryotherapy were effective in the treatment of Coats' disease with exudative retinal detachment.
We retrospectively registered our study, The trial registration number (TRN) is ChiCTR-ONC-17011161 and date of registration is April 16, 2017.
探讨玻璃体内注射雷珠单抗、激光凝固术及冷冻疗法治疗3期渗出性视网膜脱离型科茨病的疗效。
17例3期科茨病患者纳入本研究。所有患眼均首先接受玻璃体内注射雷珠单抗治疗,后续治疗根据视网膜下液吸收情况而定,包括冷冻疗法和激光光凝术。两次治疗间隔≥1个月时进行重复治疗。平均随访时间为24.12±5.99个月。主要数据评估和结果测量包括患者视力、眼压(IOP)、光学相干断层扫描(OCT)、裂隙灯检查、间接检眼镜检查、彩色多普勒成像(CDI)和彩色眼底图像分析。比较组间以下变量:异常血管变化、视网膜下液和渗出物吸收情况、视网膜复位情况及并发症。最终随访结果用于确定治疗效果。
纳入的17例患者中,男性占88.24%,女性占11.76%。术前12只眼视力低于0.02,术后8只眼视力低于0.02。7只眼视力提高,占病例数的41.18%,7只眼视力不变,占病例数的41.18%。3例患者因年龄过小未接受手术,占病例数的17.65%。最佳视力为0.1。患者接受治疗1至5次,平均每人2.82±0.95次。术前和术后眼压无统计学显著差异(t = 1.580,p = 0.135)。然而,术前和术后视网膜脱离高度有统计学显著差异(配对样本Wilcoxon符号秩检验,z = 3.517,p = 0.000)。结果还显示,所有患者视网膜下液均有不同程度吸收,部分新生血管消退。所有患者均成功接受激光和冷冻手术治疗。随访期间未观察到眼部或全身并发症。
玻璃体内注射雷珠单抗(IVR)、激光凝固术和冷冻疗法治疗渗出性视网膜脱离型科茨病有效。
我们对本研究进行了回顾性注册,试验注册号(TRN)为ChiCTR-ONC-17011161,注册日期为2017年4月16日。